You have full text access to this OnlineOpen article

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers

  1. Michele Follen M.D., Ph.D.1,†,*,
  2. Frank L. Meyskens Jr. M.D.2,
  3. Ronald D. Alvarez M.D.3,
  4. Joan L. Walker M.D.4,
  5. Maria C. Bell M.D.5,
  6. Karen Adler Storthz Ph.D.6,
  7. Jagannadha Sastry Ph.D.7,
  8. Krishnendu Roy Ph.D.8,
  9. Rebecca Richards-Kortum Ph.D.8,
  10. Terri L. Cornelison M.D., Ph.D.9

Article first published online: 22 OCT 2003

DOI: 10.1002/cncr.11674

Issue

Cancer

Cancer

Special Issue: Proceedings of the Second International Conference on Cervical Cancer

Supplement: Second International Conference on Cervical Cancer

Volume 98, Issue Supplement S9, pages 2044–2051, 1 November 2003

Additional Information

How to Cite

Follen, M., Meyskens, F. L., Alvarez, R. D., Walker, J. L., Bell, M. C., Adler Storthz, K., Sastry, J., Roy, K., Richards-Kortum, R. and Cornelison, T. L. (2003), Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer, 98: 2044–2051. doi: 10.1002/cncr.11674

Author Information

  1. 1

    Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Chao Family Comprehensive Cancer Center, Orange, California

  3. 3

    University of Alabama Medical Center, Birmingham, Alabama

  4. 4

    Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  5. 5

    Obstetrics & Gynecology Ltd., Sioux Valley Hospital, University of South Dakota Medical Center, Sioux Falls, South Dakota

  6. 6

    Department of Basic Sciences, The University of Texas Health Sciences Center at Houston Dental Branch, Houston, Texas

  7. 7

    Department of Veterinary Sciences, The University of Texas M. D. Anderson Cancer Center Science Park, Bastrop, Texas

  8. 8

    Department of Biomedical Engineering, The University of Texas, Austin, Texas

  9. 9

    Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland

  1. †

    Fax: (713) 792-4856

*Center for Biomedical Engineering, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 193, Houston, TX 77030

Publication History

  1. Issue published online: 22 OCT 2003
  2. Article first published online: 22 OCT 2003
  3. Manuscript Accepted: 21 JAN 2003
  4. Manuscript Received: 31 OCT 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (883K)

Keywords:

  • cervical cancer;
  • cervical intraepithelial neoplasia (CIN);
  • chemoprevention;
  • micronutrients;
  • human papillomavirus (HPV);
  • vaccines;
  • antiviral agents;
  • peptides

Abstract

At the Second International Conference on Cervical Cancer, held April 11–14, 2002, experts in cervical cancer prevention, detection, and treatment reviewed the need for more research in chemoprevention, including prophylactic and therapeutic vaccines, immunomodulators, peptides, and surrogate endpoint biomarkers. Investigators and clinicians noted the need for more rigorous Phase I randomized clinical trials, more attention to the risk factors that can affect study results in this patient population, and validation of optical technologies that will provide valuable quantitative information in real time regarding disease regression and progression. They discussed the role of the human papillomavirus (HPV) in cervical cancer development and the importance of developing strategies to suppress HPV persistence and progression. Results in Phase I randomized clinical trials have been disappointing because few have demonstrated statistically significant regression attributable to the agent tested. Researchers recommended using a transgenic mouse model to test and validate new compounds, initiating vaccine and immunomodulator trials, and developing immunologic surrogate endpoint biomarkers. Cancer 2003;98(9 Suppl):2044–2051. © 2003 American Cancer Society.

View Full Article (HTML) Get PDF (883K)